AIkido Pharma Announces Dr. Rachel Yehuda's Appearance on CBS News

Rhea-AI Summary

AIkido Pharma Inc. (Nasdaq: AIKI) announced Dr. Rachel Yehuda's appearance on CBS News discussing a recent FDA-approved trial involving a psychedelic drug aimed at treating PTSD. The segment highlights a former Marine's struggles with PTSD and his newfound hope through this research. AIkido expresses support for Dr. Yehuda's work and emphasizes its commitment to veterans. The company, founded in 1967, is also involved in developing anti-cancer therapeutics and a broad-spectrum antiviral platform targeting multiple viruses.

Positive

• Collaboration with renowned institutions like The University of Texas and University of Maryland enhances research credibility.
• Development of innovative therapies for unmet medical needs in oncology, including pancreatic and prostate cancer.

Negative

• None.

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Rachel Yehuda appeared on CBS News discussing the results of a recent FDA-approved trial using a psychedelic drug.  CBS News national security correspondent David Martin talks with a former Marine whose two tours in Iraq presaged twelve years of nightmares, panic attacks and failed relationships – and who now finds hope.  The video segment is available at:

https://www.cbsnews.com/video/new-hope-in-treating-ptsd-with-psychedelic-drugs/

The Company is a proud supporter of Dr. Yehuda's research, and we are committed to continuing to support our veterans.  The video segment's showcase of this important research is both inspiring and exciting. 

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:      

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:   

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-announces-dr-rachel-yehudas-appearance-on-cbs-news-301454412.html

SOURCE AIkido Pharma Inc.

FAQ

What did AIkido Pharma announce on January 5, 2022?

AIkido Pharma announced Dr. Rachel Yehuda's CBS News appearance discussing results from an FDA-approved psychedelic drug trial for PTSD.

What is the significance of Dr. Yehuda's research for veterans?

Dr. Yehuda's research offers hope for treating PTSD, which significantly impacts veterans' lives.

What therapeutic areas is AIkido Pharma focusing on?

AIkido Pharma is focusing on oncology, specifically treatments for pancreatic and prostate cancer, as well as antiviral therapies.

Where can I watch the CBS News segment featuring Dr. Yehuda?

The CBS News segment can be viewed on their official website at the link provided in the press release.